Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Never seen such a loss
View:
Post by Deadornot on Apr 05, 2021 5:51pm

Never seen such a loss

due to EMOTIONS. If you look at the facts, we should be going up. 

We're buying a company that brings in roughly $12 million per year (according to a link Jony linked the other day). Q1 we started testing travellers for COVID-19 for flights going to China, Barbados, and other (I think Q1 alone will be north of $4 million). Q4 was good. With this company we are buying, we are USING ARISTOTLE. $1,500 per test x 3000 people is $4.5 million alone just with this AVRT program. This does not include the multiple tests that the Chief Medical Officer of Care Oncology said they would do. So double that $4.5 million. 

I understand the frustration.... I AM FRUSTRATED that we didn't shoot up to $5 along with a halt. But guys, think of where we'll be in 6 months.
Comment by Skrit37 on Apr 05, 2021 5:56pm
Your assuming all 3000 patients are female then? Do you know this for a fact?
Comment by Deadornot on Apr 05, 2021 5:59pm
Aristotle is available for both genders?
Comment by Skrit37 on Apr 05, 2021 6:04pm
Female panel was going to be introduced 1st....I don't believe this has changed
Comment by Deadornot on Apr 05, 2021 6:06pm
Maybe that's why Tripp said 5,000 people in the CC and 3,000 in the NR. 3000 female and 2000 male?
Comment by Liked2Think on Apr 05, 2021 6:06pm
I missed the $12M per year can someone else post that again for me. 3000 patients currently.  Pretty sure they already know they have cancer already and what kind of cancer since they are being treated by Care already.  So does this mean they need an Aristotle test every 3 months to determine how well things are going?  I thought the test detected cancer only and it didnt detect ...more  
Comment by Deadornot on Apr 05, 2021 6:10pm
The NR says "The partnership also gives us the necessary infrastructure to correctly cater to employers, where we go next”. Further updates on the AVRT program and the acquisition will come in the weeks ahead." I believe they're going to start off with AVRT and Care Oncology and work their way. Also, it says that it is 3000 patients PLUS family members
Comment by Deadornot on Apr 05, 2021 5:58pm
"The partnership also gives us the necessary infrastructure to correctly cater to employers, where we go next”.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities